Therapeutic material
US11311646B2 · kind B2 · utility
0Cited by
0References
11Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 29, 2017 |
| Grant date | Apr 26, 2022 |
| Priority date | — |
| Expiry date | Nov 29, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2430/02
- WIPO fieldMaterials, metallurgy
- WIPO sectorChemistry
Abstract
A bioactive glass composition for use in treating bone cancer includes 0.5-10 mol % gallium oxide or 1.0-20 mol % gallium nitrate/halide; 25 to 75 mol % silicon dioxide; 10 to 30 mol % calcium oxide and/or strontium oxide; up to 30 mol % sodium oxide; and up to 15 mol % phosphorous pentoxide. It may further comprise magnesium and/or potassium oxide. The bioactive glass composition may be positioned within a patient's bone post-surgery to promote apatite formation and to release gallium ions having a toxic effect on any remaining cancerous cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.